CRDF

Cardiff Oncology, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-24

Figures on this page computed 2026-11-08 13:03 UTC

Last close

0.87USD

Market data, 2026-11-04

CRDF: weekly closes from 1.67 on 2026-05-15 to 0.87 on 2026-11-04, a move of -48.0%. Prices in USD.

Weekly closes, 2026-05-15 to 2026-11-04

Over that span: -48.0%

Except where said otherwise: 10-K for 2025, filed 2026-02-24

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-067464
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-24
The filing itself
-170.3%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-067464
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-08-11
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-08-11
The filing itself
-7732.0%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-067464
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
The filing itself
-6402.5%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-067464
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
The filing itself
0.02Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-067464
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-08-11
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Margins is the furthest below its sector's middle: 0.02 against 0.23 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.35x

1.45x

1.44x

0.27x

0.05x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-02-24

Sales1.35x
Its own average over 10 years, 438.4K.
Profit1.45x
Its own average over 10 years, -31.6M.
Free cash flow1.44x
Its own average over 10 years, -26.4M.
Debt0.27x
Its own average over 10 years, 3.1M.
Price0.05x
Its own average over 11 years, 18. Market data, 2026-11-04

Price is furthest from its own average, at 0.05 times.

The filed years, as a table

Each line is 100 at 2016-12-31, the first year we hold.

Filed year	Sales	Shares in issue
2016-12-31	100.0	100.0
2017-12-31	132.6	114.5
2018-12-31	99.3	554.0
2019-12-31	64.2	1,420.4
2020-12-31	96.0	4,963.5
2021-12-31	94.2	9,280.2
2022-12-31	101.3	10,366.8
2023-12-31	128.1	10,622.9
2024-12-31	179.2	11,329.8
2025-12-31	155.6	15,892.8

How sales was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001193125-26-067464
Reported in: USD

The filing itself

How shares in issue was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001193125-26-067464
Reported in: USD

The filing itself

Figures behind the shape

Growth

10.1%

faster is higher, placed against 4,950 companies as of 2026-11-07

Five-year revenue growth rate10.1%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
One-year change in net income-0.9%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Returns on capital

-170.3%

higher is higher, placed against 5,089 companies as of 2026-11-07

Return on invested capital-170.3%
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-067464
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-08-11
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-08-11
The filing itself
Return on equity-101.0%
Net Income / Shareholders' Equity x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-067464
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-08-11
The filing itself
Return on assets-74.1%
Net Income / Total Assets x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-067464
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-08-11
The filing itself

Margins

-8256.3%

wider is higher, placed against 3,412 companies as of 2026-11-07

Gross marginn/a
We do not hold this figure for this company, so there is nothing to place.
Gross Profit / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-067464
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
The filing itself
Operating margin-8256.3%
Operating Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-067464
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
The filing itself
Net margin-7732.0%
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-067464
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
The filing itself
Free cash flow margin-6402.5%
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-067464
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
The filing itself

Price

1.2x

cheaper is higher, placed against 4,362 companies as of 2026-11-07

Price to earningsn/a
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-067464
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-24
The filing itself
Price to book1.2x10-Q for 2025, filed 2026-08-11
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001193125-26-344545
Reported in
USD
- computed
- 10-Q for 2025, filed 2026-08-11
- computed
- 10-K for 2025, filed 2026-02-24
The filing itself
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-067464
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-08-11
- 10-K for 2025, filed 2026-02-24
The filing itself
Price to sales ratio89.6x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001193125-26-067464
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
The filing itself

Safety

0.02

safer is higher, placed against 3,227 companies as of 2026-11-07

Debt to equity0.02
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-067464
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-08-11
The filing itself
Current ratio3.6710-Q for 2025, filed 2026-08-11
Current Assets / Current Liabilities
Source
computed
Fiscal year
2025
Accession
0001193125-26-344545
Reported in
USD
- 10-Q for 2025, filed 2026-08-11
- 10-Q for 2025, filed 2026-08-11
The filing itself
Interest coveragen/a
We do not hold this figure for this company, so there is nothing to place.
Operating Income / Interest Expense
Source
computed
Fiscal year
2025
Accession
0001193125-26-067464
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
The filing itself
Altman Z-Score-9.55
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
Source
computed
Taken on
2026-11-07
Reported in
USD
- Computed from the 10-K for 2025, filed 2026-02-24
- Computed from the 10-K for 2025, filed 2026-02-24
- Computed from the 10-K for 2025, filed 2026-02-24
- Computed from the 10-K for 2025, filed 2026-02-24
- Computed from the 10-K for 2025, filed 2026-02-24

What it pays out

n/a

We do not hold this figure for this company, so there is nothing to place.

more, and better covered, is higher, with no cohort held

Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
Source
computed
Fiscal year
2025
Accession
0001193125-26-067464
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- Computed from the 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
The filing itself
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Share a finding

A link to the finding, not to you: it carries nothing about your account.